SAN FRANCISCO — In a case addressing the patentability of biological discoveries, a federal judge has disarmed a biotechnology company that was wielding a patent to block competitors from offering a new form of noninvasive prenatal testing.
In a 20-page order issued Wednesday, U.S. District Judge Susan Illston of the Northern District of California rejected a patent asserted by Sequenom Inc., agreeing with a rival that the patent combined the discovery of a nonpatentable law of nature and conventional scientific methods.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
